title: High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
abstract: BACKGROUND
  Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship. We evaluated the feasibility and toxicity of a high-dose IFO-plus-ADM combination.
  
  
  METHODS
  Fourteen patients with advanced disease and nine patients in adjuvant setting received IFO 12.5 g/m2 in 120-hour continuous infusion with Mesna uroprotection and ADM 20 mg/m2 on days 1-3 and G-CSF every three weeks.
  
  
  RESULTS
  Twenty-three patients received 89 chemotherapy cycles (70 cycles at full dose). Seventeen patients received the planned treatment, and nine patients required dose reductions. We observed grade 3-4 neutropenia in 52 cycles (59%)/20 patients; grade 3-4 thrombocytopenia in 16 cycles (18%)/nine patients; grade 3-4 anaemia in 24 cycles (27%)/11 patients. Eight patients experienced febrile neutropenia and six patients required blood transfusions.
  
  
  CONCLUSIONS
  While feasible, this regimen showed heavy toxicity. Nevertheless, 74% of the patients were able to complete the planned treatment. Adjustment of the schedule of IFO continuous infusion to improve this combination is currently under investigation.
authors.affiliation: Department of Medical Oncology, European Institute of Oncology, Milan, Italy. mdepas@ieo.cilea.it
authors.forename: T
authors.initials: T
authors.lastname: De Pas
authors.forename: F
authors.initials: F
authors.lastname: De Braud
authors.forename: L
authors.initials: L
authors.lastname: Orlando
authors.forename: F
authors.initials: F
authors.lastname: Nolè
authors.forename: E
authors.initials: E
authors.lastname: Munzone
authors.forename: M G
authors.initials: MG
authors.lastname: Zampino
authors.forename: N
authors.initials: N
authors.lastname: Fazio
authors.forename: M S
authors.initials: MS
authors.lastname: Aapro
authors.forename: A
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D005240:Feasibility Studies; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007262:Infusions, Intravenous; D008297:Male; D015080:Mesna / Q000008:administration & dosage; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D004317:Doxorubicin; D015080:Mesna; D007069:Ifosfamide